- Home
- ABEO vs CLLS Comparison
ABEO vs CLLS Comparison
Compare ABEO & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEO
- CLLS
- Stock Information
- Founded
- ABEO 1974
- CLLS 1999
- Country
- ABEO United States
- CLLS France
- Employees
- ABEO N/A
- CLLS N/A
- Industry
- ABEO Biotechnology: Pharmaceutical Preparations
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- ABEO Health Care
- CLLS Health Care
- Exchange
- ABEO Nasdaq
- CLLS Nasdaq
- Market Cap
- ABEO 281.0M
- CLLS 299.0M
- IPO Year
- ABEO 1980
- CLLS 2007
- Fundamental
- Price
- ABEO $5.53
- CLLS $3.63
- Analyst Decision
- ABEO Strong Buy
- CLLS Buy
- Analyst Count
- ABEO 6
- CLLS 1
- Target Price
- ABEO $18.17
- CLLS $8.00
- AVG Volume (30 Days)
- ABEO 1.0M
- CLLS 194.3K
- Earning Date
- ABEO 11-13-2025
- CLLS 11-03-2025
- Dividend Yield
- ABEO N/A
- CLLS N/A
- EPS Growth
- ABEO N/A
- CLLS N/A
- EPS
- ABEO 0.99
- CLLS N/A
- Revenue
- ABEO $400,000.00
- CLLS $63,438,000.00
- Revenue This Year
- ABEO N/A
- CLLS N/A
- Revenue Next Year
- ABEO $324.71
- CLLS $66.76
- P/E Ratio
- ABEO $5.60
- CLLS N/A
- Revenue Growth
- ABEO N/A
- CLLS 223.09
- 52 Week Low
- ABEO $3.93
- CLLS $1.10
- 52 Week High
- ABEO $7.54
- CLLS $5.48
- Technical
- Relative Strength Index (RSI)
- ABEO 48.54
- CLLS 50.13
- Support Level
- ABEO $5.29
- CLLS $3.43
- Resistance Level
- ABEO $5.60
- CLLS $5.48
- Average True Range (ATR)
- ABEO 0.26
- CLLS 0.35
- MACD
- ABEO 0.05
- CLLS -0.09
- Stochastic Oscillator
- ABEO 63.39
- CLLS 11.49
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.